Pfizer Inc., the world's largest pharmaceutical company, is struggling to find growth. Just like many of its peers, the company is suffering as sales of legacy drugs slide due to the loss of exclusive manufacturing rights.
Our two big FTSE 100 pharmaceuticals companies have had a mixed 12 months - GlaxoSmithKline (LSE: GSK)(NYSE: GSK.US) has seen its shares lose 16% to today's 1,374p, while AstraZeneca (LSE: AZN)(NYSE: AZN.US) has enjoyed a rise of 26% to ...
If you were to ask investors at the beginning of the year whether you should invest in GlaxoSmithKline (LSE: GSK) or AstraZeneca (LSE: AZN), I think most would have picked the former rather than the latter.
You probably know everything about GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) by now: a bribery scandal in China, falling earnings and a patent cliff have all weighed on its equity valuation in recent times.